Notice of Intent to Publish a Funding Opportunity Announcement for Copy of Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) (R21 Clinical Trial Not Allowed)
Notice Number:
NOT-CA-22-027

Key Dates

Release Date:
December 27, 2021
Estimated Publication Date of Funding Opportunity Announcement:
February 03, 2022
First Estimated Application Due Date:
June 16, 2022
Earliest Estimated Award Date:
March 01, 2023
Earliest Estimated Start Date:
April 01, 2023
Related Announcements

NOT-CA-22-026 - Notice of Intent to Publish a Funding Opportunity Announcement for Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) (R01 Clinical Trial Not Allowed)

Issued by

National Cancer Institute (NCI)

Purpose

This Notice is to inform the research community that the National Cancer Institute intends to issue a Funding Opportunity Announcement (FOA) to solicit applications for the Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) program. The STRIPE program seeks to support pre-clinical research projects utilizing state-of-the-art cancer biology methods and model systems that study how radiopharmaceutical therapy (RPT) agents affect the biology of normal tissue, tumor cells and the tumor microenvironment. Ideally, proposed aims will be designed to test hypotheses on how RPT dynamically impacts cancer biology processes, which can serve as the pre-clinical basis for developing new targeting strategies and approaches. Studies supported by this PAR will ultimately inform the rationale and design of new RPT-based clinical trials.

This Notice is being provided to allow potential applicants sufficient time to develop a responsive proposal. The STRIPE program FOAs will utilize the R21 activity code for pre-clinical research. Applications seeking support for clinical trials will not be allowed. The FOAs are expected to be published in February 2022 with an expected application due date in June 2022.

Research Initiative Details

While the physical parameters of radionuclide particle emissions are well established, knowledge of their biological effects beyond DNA lesioning events is scant. Moreover, few studies are conducted to examine the effects of the specific types of radiation used in RPT in combination with other therapeutic agents. Mechanistic studies using current “-omic” tools and relevant pre-clinical model systems have strong potential to elucidate new targets (e.g., pathways, phenotypes, microenvironment) for both radiopharmaceutical agents used alone and in combination with conventional targeted therapies. A goal of the STRIPE program is to strengthen and expand pre-clinical cancer biology perspectives in RPT research toward the goal of developing new strategies that leverage the full range of RPT’s unique properties in treatment of cancers. Examples of pre-clinical research supported through this PAR include, but not limited to the following activities:
• Identification of new targets and/or targeting strategies for RPT;
• Selective targeting of cancer specific pathway, organelle, or process;
• Development of synthetic lethality approaches;
• Advancing PD biomarkers or microdosimetry based on theranostic capabilities;
• Testing of novel RPT molecular targeted therapy combinations;
• Understanding polypharmacy mechanisms for RPT-drug combinations;
• Measurement of RPT effects to optimize treatment regimens for recalcitrant resistant or metastatic disease;
• Examination of RPT effects on organs at risk to improve therapeutic index;
• Mechanisms of adaptation to RPT that underlie emergence of resistance, treatment response (success or failure).

The intent of this FOA is to support pre-clinical experiments. Responsive proposals may include human subjects research; however, human clinical trials will not be supported through this PAR.
A project that focuses entirely on developing computational or in silico modeling of RPT response(s) is not responsive to this PAR. Multi-PI applications will be encouraged to maximize the potential of team science efforts and combine capabilities that might be necessary to fulfill the need for specialized multidisciplinary research at the intersection between RPT drug development and cancer biology research.
 

Funding Information
Estimated Total Funding

TBD

Expected Number of Awards

6

Estimated Award Ceiling

The combined budget for direct costs for the two-year project period may not exceed $275,000. No more than $200,000 may be requested in any single year.

Primary Assistance Listing Number(s)

93.393, 93.394, 93.395, 93.396, 93.399, 93.286

Anticipated Eligible Organizations
Public/State Controlled Institution of Higher Education
Private Institution of Higher Education
Nonprofit with 501(c)(3) IRS Status (Other than Institution of Higher Education)
Small Business
For-Profit Organization (Other than Small Business)
State Government
Indian/Native American Tribal Government (Federally Recognized)
County governments
Independent school districts
Indian/Native American Tribally Designated Organization (Native American tribal organizations (other than Federally recognized tribal governments)
U.S. Territory or Possession
Indian/Native American Tribal Government (Other than Federally Recognized)
Non-domestic (non-U.S.) Entity (Foreign Organization)
Regional Organization
Eligible Agencies of the Federal Government

Applications are not being solicited at this time. 

Inquiries

Please direct all inquiries to:

Michael Graham Espey, Ph.D.

National Cancer Institute (NCI)

240-276-7619

Jacek Capala, Ph.D.
National Cancer Institute (NCI)
240-276-5690
jc801j@nih.gov